
ESLA Stock Forecast & Price Target
ESLA Analyst Ratings
Bulls say
Estrella Immunopharma Inc has enhanced its clinical and financial standing through the successful completion of an $8 million financing round, facilitating the advancement of its EB103 therapy into the Phase II portion of its study. The ongoing development of the EB104 dual CD19/CD22 program, alongside potential strategic partnerships, positions the company to address significant market opportunities in treating B-cell malignancies and autoimmune conditions. With encouraging early safety and efficacy results for EB103, including the onboarding of the first Phase II patient, Estrella’s innovative Artemis Technology platform is poised to unlock new avenues in CAR-T therapy, particularly for solid tumors, indicating a strong potential for future growth.
Bears say
Estrella Immunopharma Inc faces significant financial concerns, particularly regarding potential future dilution stemming from the ongoing stock decline. Modifications to financial assumptions have led to a reduction in target price from $16.0 to $8.0, indicating a more conservative financial outlook as the company evaluates its strategic priorities and pipeline development. The lack of clarity surrounding updates on partnering and development sequencing could further hinder investor confidence and the company’s market performance.
This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
ESLA Analyst Forecast & Price Prediction
Start investing in ESLA
Order type
Buy in
Order amount
Est. shares
0 shares